Previous 10 | Next 10 |
Under priority review status, the FDA has accepted ADC Therapeutics' (ADCT) marketing application for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma ((DLBCL))Agency's action date is set at May 21, 2021.Lonca is also being evaluate...
Prescription Drug User Fee Act target action date of May 21, 2021 ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs)...
ADC Therapeutics SA (ADCT) Q3 2020 Earnings Conference Call November 12, 2020 8:30 AM ET Company Participants Amanda Hamilton – Manager-Investor Relations Chris Martin – Chief Executive Officer Jay Feingold – Chief Medical Officer Jenn Creel – Chief Financial Offic...
ADC Therapeutics (ADCT): Q3 Non-GAAP EPS of -$0.58; GAAP EPS of -$0.29.Cash and cash equivalents of $494.6MPress Release For further details see: ADC Therapeutics reports Q3 results
- Submitted BLA for lead program, Lonca, for treatment of relapsed or refractory DLBCL on September 21, 2020 - Commercial launch activities on track for potential U.S. launch of Lonca in mid-2021 - Initiated Phase 3 confirmatory trial of Lonca in combination with ritux...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced th...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced th...
Several presentations highlight lead candidate loncastuximab tesirine (Lonca); BLA under FDA review for the treatment of relapsed or refractory diffuse large B-cell lymphoma Updated preliminary data from pivotal Phase 2 trial of camidanlumab tesirine (Cami) in Hodgkin lymphoma...
The first participant has been dosed in an additional arm of a Phase 1b clinical trial evaluating ADC Therapeutics' (ADCT) antibody-drug conjugate camidanlumab tesirine (Cami) (formerly ADCT-301), combined with Merck's (MRK) Keytruda (pembrolizumab), in patients with advanced solid ...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced th...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...